178 related articles for article (PubMed ID: 34790577)
21. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects.
Lee HJ; Moon Y; Choi J; Heo JD; Kim S; Nallapaneni HK; Chin YW; Lee J; Han SY
Biomol Ther (Seoul); 2022 Jul; 30(4):360-367. PubMed ID: 35264466
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
Iida H; Fujikawa R; Kozaki R; Harada R; Hosokawa Y; Ogawara KI; Ohno T
J Pharmacol Exp Ther; 2020 Jun; 373(3):361-369. PubMed ID: 32217770
[TBL] [Abstract][Full Text] [Related]
24. AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2022 Oct; 223():106132. PubMed ID: 35659529
[TBL] [Abstract][Full Text] [Related]
25. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting TRK Proteins in Clinical Cancer Therapy.
Lange AM; Lo HW
Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29617282
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
[TBL] [Abstract][Full Text] [Related]
28. Toward in vivo proof of binding of
Wuest M; Bailey JJ; Dufour J; Glubrecht D; Omana V; Johnston TH; Brotchie JM; Schirrmacher R
EJNMMI Res; 2022 Jul; 12(1):46. PubMed ID: 35907096
[TBL] [Abstract][Full Text] [Related]
29. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
30. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
31. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
SenthilKumar G; Fisher MM; Skiba JH; Miller MC; Brennan SR; Kaushik S; Bradley ST; Longhurst CA; Buehler D; Nickel KP; Iyer G; Kimple RJ; Baschnagel AM
Mol Cancer Ther; 2020 Jun; 19(6):1255-1265. PubMed ID: 32371583
[TBL] [Abstract][Full Text] [Related]
32. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
33. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
[TBL] [Abstract][Full Text] [Related]
36. Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.
Assimakopoulou M; Kondyli M; Gatzounis G; Maraziotis T; Varakis J
BMC Cancer; 2007 Oct; 7():202. PubMed ID: 17971243
[TBL] [Abstract][Full Text] [Related]
37. FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Luo H; Quan J; Xiao H; Luo J; Zhang Q; Pi G; Ye Y; He R; Liu Y; Su X; Zhao L; Wang G
Oncol Rep; 2018 May; 39(5):2270-2278. PubMed ID: 29517107
[TBL] [Abstract][Full Text] [Related]
38. Neurotrophin Trk Receptors: New Targets for Cancer Therapy.
Meldolesi J
Rev Physiol Biochem Pharmacol; 2018; 174():67-79. PubMed ID: 28884193
[TBL] [Abstract][Full Text] [Related]
39. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD
Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940
[TBL] [Abstract][Full Text] [Related]
40. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
